Oramed Pharmaceuticals (ORMP) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $4.07, -2.63% vs the prior close of $4.18.
- Volume 277.08K shares, 1.4x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ORMP dips 2.6% to $4.07, a 1-month low. Closed at $4.07, -2.63% vs the prior close of $4.18. Day range $3.99–$4.19, opened at $4.19.
ORMP daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ORMP dips 2.6% to $4.07, a 1-month low
- Closed at $4.07, -2.63% vs the prior close of $4.18. Day range $3.99–$4.19, opened at $4.19.
- Volume was 277.08K shares, 1.4x its 50-day average of 192.05K.
- Price is -12.3% vs its 50-day average ($4.64) and +2.1% vs its 200-day average ($3.99).
- 52-week range $2.09–$5.47; today's close sits at 59% of that range, 25.6% below the 52-week high.
Oct 15, 2026 — ORMP rises 1.0% to $4.18
- Closed at $4.18, +0.97% vs the prior close of $4.14. Day range $4.15–$4.28, opened at $4.18.
- Volume was 128.20K shares, 0.7x its 50-day average of 192.73K.
- Price is -10.0% vs its 50-day average ($4.64) and +5.0% vs its 200-day average ($3.98).
- 52-week range $2.09–$5.47; today's close sits at 62% of that range, 23.6% below the 52-week high.
Oct 14, 2026 — ORMP dips 0.7% to $4.14, a 1-month low, 3 down days in a row
- Closed at $4.14, -0.72% vs the prior close of $4.17. Day range $4.12–$4.22, opened at $4.12.
- Volume was 146.60K shares, 0.8x its 50-day average of 194.65K.
- Price is -10.9% vs its 50-day average ($4.65) and +4.2% vs its 200-day average ($3.97).
- 52-week range $2.09–$5.47; today's close sits at 61% of that range, 24.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ORMP dips 2.3% to $4.17, a 1-month low
- Closed at $4.17, -2.34% vs the prior close of $4.27. Day range $4.15–$4.28, opened at $4.28.
- Volume was 113.80K shares, 0.6x its 50-day average of 198.03K — lighter than usual.
- Price is -10.4% vs its 50-day average ($4.65) and +5.1% vs its 200-day average ($3.97).
- 52-week range $2.09–$5.47; today's close sits at 62% of that range, 23.8% below the 52-week high.
Oct 12, 2026 — ORMP dips 1.4% to $4.27
- Closed at $4.27, -1.39% vs the prior close of $4.33. Day range $4.21–$4.35, opened at $4.34.
- Volume was 73.20K shares, 0.4x its 50-day average of 200.74K — lighter than usual.
- Price is -8.3% vs its 50-day average ($4.66) and +7.7% vs its 200-day average ($3.96).
- 52-week range $2.09–$5.47; today's close sits at 64% of that range, 21.9% below the 52-week high.
Oct 9, 2026 — ORMP jumps 3.1% to $4.33
- Closed at $4.33, +3.10% vs the prior close of $4.20. Day range $4.15–$4.34, opened at $4.17.
- Volume was 193.50K shares, 1.0x its 50-day average of 199.87K.
- Price is -6.9% vs its 50-day average ($4.65) and +9.4% vs its 200-day average ($3.96).
- 52-week range $2.09–$5.47; today's close sits at 66% of that range, 20.8% below the 52-week high.
Oct 8, 2026 — ORMP slides 3.9% to $4.20, a 1-month low, 3 down days in a row
- Closed at $4.20, -3.89% vs the prior close of $4.37. Day range $4.16–$4.36, opened at $4.36.
- Volume was 166.50K shares, 0.8x its 50-day average of 199.15K.
- Price is -9.7% vs its 50-day average ($4.65) and +6.3% vs its 200-day average ($3.95).
- 52-week range $2.09–$5.47; today's close sits at 62% of that range, 23.2% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — ORMP ends flat (-0.2%) to $4.37, a 1-month low
- Closed at $4.37, -0.23% vs the prior close of $4.38. Day range $4.35–$4.45, opened at $4.43.
- Volume was 84.70K shares, 0.4x its 50-day average of 199.71K — lighter than usual.
- Price is -5.9% vs its 50-day average ($4.64) and +10.8% vs its 200-day average ($3.94).
- 52-week range $2.09–$5.47; today's close sits at 67% of that range, 20.1% below the 52-week high.
Oct 6, 2026 — ORMP slides 3.7% to $4.38, a 1-month low
- Closed at $4.38, -3.74% vs the prior close of $4.55. Day range $4.36–$4.58, opened at $4.55.
- Volume was 96.20K shares, 0.5x its 50-day average of 199.25K — lighter than usual.
- Price is -5.6% vs its 50-day average ($4.64) and +11.2% vs its 200-day average ($3.94).
- 52-week range $2.09–$5.47; today's close sits at 68% of that range, 19.9% below the 52-week high.
Oct 5, 2026 — ORMP rises 1.3% to $4.55
- Closed at $4.55, +1.34% vs the prior close of $4.49. Day range $4.43–$4.57, opened at $4.50.
- Volume was 104.10K shares, 0.5x its 50-day average of 199.86K — lighter than usual.
- Price is -1.8% vs its 50-day average ($4.64) and +15.8% vs its 200-day average ($3.93).
- 52-week range $2.09–$5.47; today's close sits at 73% of that range, 16.8% below the 52-week high.
Oct 2, 2026 — ORMP ends flat (+0.2%) to $4.49
- Closed at $4.49, +0.22% vs the prior close of $4.48. Day range $4.39–$4.57, opened at $4.53.
- Volume was 178.30K shares, 0.9x its 50-day average of 199.34K.
- Price is -2.9% vs its 50-day average ($4.63) and +14.5% vs its 200-day average ($3.92).
- 52-week range $2.09–$5.47; today's close sits at 71% of that range, 17.9% below the 52-week high.
ORMP latest news & SEC filings
Every SEC filing by or about ORMP in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gabay Avraham sold 20,000 shares at $4.51 (≈$90.20K) on Oct 1, 2026; now holds 861,076
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hexter Joshua sold 30,000 shares at $4.51 (≈$135.33K) on Oct 1, 2026; now holds 1,328,130
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kidron Nadav received an award of 349,497 shares on Sep 24, 2026; now holds 3,771,740
- Kidron Nadav received an award of 368,765 shares on Sep 24, 2026; now holds 4,140,505
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hexter Joshua received an award of 75,455 shares on Sep 24, 2026; now holds 1,148,839
- Hexter Joshua received an award of 209,291 shares on Sep 24, 2026; now holds 1,358,130
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: $78.16M (prior year $13.29M) (+488.2% vs Jun 30, 2025)
- Diluted EPS: $1.84 (prior year $0.31) (+493.5% vs Jun 30, 2025)
Aug 3, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Aug 3, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Aug 3, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Jul 22, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 8.01 — Reported other events the company considers important.
Jun 29, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade ORMP
- Last results release: Nov 17, 2025 (8-K Item 2.02). Previous ones: Oct 24, 2025, Nov 10, 2022. Based on that rhythm, the next report is likely around Feb 16, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.60% (largest 4.1%).
- Liquidity: about 147.48K shares (≈$600.26K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $4.07 vs a range of $2.09–$5.47 (59% of the range).
- Dividends: last ex-dividend date Jan 16, 2026 ($0.25/share); 1 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 8 sales; latest: Joshua Hexter sold 137,000 shares on Jul 1, 2026.
- Latest filings: 8-K Sep 17, 2026; 10-Q Aug 10, 2026; 8-K Jun 30, 2026.
- Share count: 41.60M shares outstanding (Aug 10, 2026), +1.4% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ORMP market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 4.19 | 4.19 | 3.99 | 4.07 | 277.08K |
| Oct 15, 2026 | 4.18 | 4.28 | 4.15 | 4.18 | 128.20K |
| Oct 14, 2026 | 4.12 | 4.22 | 4.12 | 4.14 | 146.60K |
| Oct 13, 2026 | 4.28 | 4.28 | 4.15 | 4.17 | 113.80K |
| Oct 12, 2026 | 4.34 | 4.35 | 4.21 | 4.27 | 73.20K |
| Oct 9, 2026 | 4.17 | 4.34 | 4.15 | 4.33 | 193.50K |
| Oct 8, 2026 | 4.36 | 4.36 | 4.16 | 4.20 | 166.50K |
| Oct 7, 2026 | 4.43 | 4.45 | 4.35 | 4.37 | 84.70K |
| Oct 6, 2026 | 4.55 | 4.58 | 4.36 | 4.38 | 96.20K |
| Oct 5, 2026 | 4.50 | 4.57 | 4.43 | 4.55 | 104.10K |
| Oct 2, 2026 | 4.53 | 4.57 | 4.39 | 4.49 | 178.30K |
| Oct 1, 2026 | 4.65 | 4.69 | 4.43 | 4.48 | 272.60K |
| Sep 30, 2026 | 4.70 | 4.72 | 4.66 | 4.67 | 129.20K |
| Sep 29, 2026 | 4.76 | 4.80 | 4.67 | 4.69 | 170.70K |
| Sep 28, 2026 | 4.70 | 4.78 | 4.65 | 4.75 | 110.40K |
| Sep 25, 2026 | 4.80 | 4.90 | 4.72 | 4.73 | 177.90K |
| Sep 24, 2026 | 4.71 | 4.88 | 4.65 | 4.79 | 149.30K |
| Sep 23, 2026 | 4.74 | 4.74 | 4.62 | 4.72 | 134.80K |
| Sep 22, 2026 | 4.71 | 4.84 | 4.71 | 4.75 | 145.20K |
| Sep 21, 2026 | 4.76 | 4.76 | 4.67 | 4.70 | 97.40K |
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (ORMP) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW YORK, NY. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1176309.
ORMP board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Daniel Aghion | Director | Jan 2, 2026 |
| Nadav Kidron | President and CEO | Sep 25, 2026 |
| Miriam Kidron | Chief Scientific Officer | Sep 25, 2026 |
| Arie Mayer | Director | Jan 5, 2026 |
| Yehuda Reznick | Director | Jan 5, 2026 |
| Benjamin Shapiro | Director | Jan 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Avraham Gabay | Chief Financial Officer | Sep 25, 2026 |
| Joshua Hexter | COO & CBO | Sep 25, 2026 |
| Nadav Kidron | President and CEO | Sep 25, 2026 |
| Miriam Kidron | Chief Scientific Officer | Sep 25, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 1, 2026 | Joshua Hexter | Sale | 137,000 | $4.46 |
| Jul 1, 2026 | Joshua Hexter | Sale | 137,000 | $4.46 |
| Jul 1, 2026 | Joshua Hexter | Sale | 137,000 | $4.46 |
| Jul 1, 2026 | Joshua Hexter | Sale | 137,000 | $4.46 |
| Jul 1, 2026 | Avraham Gabay | Sale | 73,360 | $4.51 |
| Jul 1, 2026 | Avraham Gabay | Sale | 73,360 | $4.51 |
| Jul 1, 2026 | Avraham Gabay | Sale | 73,360 | $4.51 |
| Jul 1, 2026 | Avraham Gabay | Sale | 73,360 | $4.51 |
ORMP financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $2.00M | $64.05M | 1.50 | $-9.14M |
| Dec 31, 2024 | — | $-19.06M | -0.48 | $-8.41M |
| Dec 31, 2023 | $1.34M | $5.09M | 0.14 | $-10.29M |
| Dec 31, 2022 | $2.70M | $-36.56M | -0.94 | $-27.92M |
| Aug 31, 2021 | $2.70M | $-22.99M | — | $-21.18M |
Latest balance sheet: total assets $369.64M, total liabilities $502.69K, cash $15.24M (as of Jun 30, 2026).
ORMP earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Nov 17, 2025 | 8-K Item 2.02 (results) | $2.34 |
| Oct 24, 2025 | 8-K Item 2.02 (results) | $2.39 |
| Nov 10, 2022 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ORMP
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.